Key facts
- This page summarizes Thomas D. Carey's Form 4 filing for SomaLogic, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jan 2024, 21:18.
Thomas D. Carey - 05 Jan 2024 Form 4 Insider Report for SomaLogic, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 05 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jan 2024, 21:18:06 UTC
- Prior SEC filing
- 12 Jun 2023
- Next SEC filing
- 02 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ruben Gutierrez, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas D. Carey filed Form 4 for SomaLogic, Inc. on 09 Jan 2024.
Change
- Previous filing in this sequence was filed on 12 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLGC
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -185,400
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 05 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 185,400
- Exercise price
- $2.74
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Thomas D. Carey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Footnote F2
On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and
Footnote F3
(Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"),
Footnote F4
(Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.